Drug wars: how AstraZeneca overtook GSK in UK pharma
GlaxoSmithKline (GSK) - Market capitalization
Glaxo (GSK) to Report Q1 Earnings: What's in the Cards?
GlaxoSmithKline: Back To The Drawing Board (NYSE:GSK) | Seeking Alpha
Glaxo Underperforms Industry in a Year: What's in Store?
Taking A Look At The Special Situation With GlaxoSmithKline (NYSE:GSK) | Seeking Alpha
Glaxosmithkline Pharmaceuticals Share Price today, Market Cap, Shareholding, Financials
GSK Needs to Show It's Kicked the Dealmaking Addiction - The Washington Post
Why are GlaxoSmithKline (GSK) shares so low? (LON:GSK) - Good Money Guide
Glaxo (GSK) Q4 Earnings Top Estimates, Xevudy Adds $1.1B in Sales | Nasdaq
Glaxo (GSK) to Report Q4 Earnings: What's in the Cards?
GlaxoSmithKline To Spin-Off Consumer Healthcare Business By Mid-2022
Better Buy: Eli Lilly vs. GlaxoSmithKline | The Motley Fool
GSK spinoff starts trading at LSE - what you need to know
Better Buy: GlaxoSmithKline vs. Eli Lilly | The Motley Fool
Haleon or GSK – which is the better play?
GSK falls victim to 'hard to please' pharma market | LSE:GSK, NYSE:GSK
GSK lines up Rs 6,400cr open offer - Times of India
London stock market listing of up to £45bn looms as GSK investors vote for demerger | GlaxoSmithKline | The Guardian
Top-10 Biggest UK-based Companies 2023 | Hantec Markets
GlaxoSmithKline Pharmaceuticals Share: Motilal Oswal Financial Services neutral on GlaxoSmithKline Pharmaceuticals; target price: Rs 1300 - The Economic Times
UK Drugmaker GSK Needs to Show It's Kicked the Dealmaking Addiction - Bloomberg
GSK spins off Haleon in biggest European listing for a decade
GlaxoSmithKline To Spin-Off Consumer Healthcare Business By Mid-2022
